Stock Chart
MYGN
Type: SELL growth_1yr
Strike: $8
Premium: $0.76
Expiry: May 15, 2026
Target: $8
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About MYGN - Myriad Genetics Inc
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines …
Key Statistics
More MYGN Analysis
This MYGN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track MYGN's price movements with trendlines, gamma walls, and key support/resistance levels.